The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.
 
Min Jin
No Relationships to Disclose
 
Shengli Yang
No Relationships to Disclose
 
Junli Liu
No Relationships to Disclose
 
Jieying Zhang
No Relationships to Disclose
 
Lei Zhao
No Relationships to Disclose
 
Dandan Yu
No Relationships to Disclose
 
Zhenyu Lin
No Relationships to Disclose
 
Pindong Li
No Relationships to Disclose
 
Jing Wang
No Relationships to Disclose
 
Jun Xue
No Relationships to Disclose
 
Hong Ma
No Relationships to Disclose
 
Jianli Hu
No Relationships to Disclose
 
Tao Zhang
No Relationships to Disclose
 
Hongli Liu
No Relationships to Disclose